| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Regeneron Pharmaceuticals is experiencing significant growth driven by a strong R&D pipeline that facilitates innovative product development and supports future revenue generation. The company has a robust product pipeline, including successful drugs like Dupixent and EYLEA HD, while recent advancements in lipid-lowering therapies like Evkeeza enhance its portfolio. This combination of innovation and established performance positions Regeneron favorably in the market. However, reliance on a few key drugs could pose risks should competitive pressures arise. |
| The price action of Regeneron Pharmaceuticals (REGN) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.3 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for REGN since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.5, and the negative at -0.2 on 2025-09-29. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (3.1) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| REGN | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-29 | 0%(0%) | 0 | 0% | 0.4 | 3.1 | -1 | |||||||
| 2025-09-28 | 0%(0%) | 0 | 0% | 0.5 | 3.8 | -1 | |||||||
| 2025-09-27 | 0%(0%) | 0 | 0% | 0.5 | 3.8 | -1 | |||||||
| 2025-09-26 | 0%(0%) | 0 | 0% | 0.5 | 3.8 | -1 | |||||||
| 2025-09-25 | 0%(0%) | 0 | 0% | 0.5 | 4.2 | -1 | |||||||
| 2025-09-24 | 0%(0%) | 0 | 0% | 0.5 | 4.2 | -1 | |||||||
| 2025-09-23 | 0%(0%) | 0 | 0% | 0.7 | 5.2 | -6 | |||||||
| 2025-09-22 | 0%(0%) | 0 | 0% | 0.8 | 5.7 | -1 | |||||||
| 2025-09-21 | 0%(0%) | 0 | 0% | 0.8 | 5.8 | -1 | |||||||
| 2025-09-20 | 0%(0%) | 0 | 0% | 0.8 | 5.8 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-09-29 17:12:04 Regeneron is committing significant investment towards enhancing its manufacturing capabilities and engaging in strategic partnerships, which show dedication to long-term growth. |
| 2025-09-29 17:12:04 Recent FDA approvals for drugs like Dupixent and Evkeeza enhance Regeneron's market presence and could convey potential revenue boosts from new indications. |
| 2025-09-29 17:12:04 Regeneron has experienced stock volatility and criticisms regarding its market position, heavy losses, and earnings misses, which are raising concerns among investors. |
| 2025-09-29 17:12:04 Regeneron's flagship drug Eylea is facing significant competition from biosimilars and identifying an ongoing decline in its sales, resulting in challenges for the company. |
| 2025-09-29 17:12:04 The consistent reporting of strong growth from drugs like Dupixent and advancements in Regeneron's pipeline indicate a strong potential for future revenue generation. |